Mackenzie Financial Corp Sells 10,308 Shares of Sarepta Therapeutics, Inc. (NASDAQ:SRPT)

Mackenzie Financial Corp reduced its stake in Sarepta Therapeutics, Inc. (NASDAQ:SRPT) by 50.2% in the fourth quarter, Holdings Channel.com reports. The fund owned 10,209 shares of the biotechnology company’s stock after selling 10,308 shares during the period. Mackenzie Financial Corp’s holdings in Sarepta Therapeutics were worth $984,000 as of its most recent filing with the Securities and Exchange Commission (SEC).

Other large investors have also recently made changes to their positions in the company. Mizuho Markets Americas LLC purchased a new stake in shares of Sarepta Therapeutics in the third quarter worth $29,813,000. Westfield Capital Management Co. LP raised its position in Sarepta Therapeutics by 40.1% during the third quarter. Westfield Capital Management Co. LP now owns 806,400 shares of the biotechnology company’s stock valued at $97,752,000 after purchasing an additional 230,618 shares in the last quarter. TD Asset Management Inc raised its position in Sarepta Therapeutics by 377.7% during the third quarter. TD Asset Management Inc now owns 204,626 shares of the biotechnology company’s stock valued at $24,805,000 after purchasing an additional 161,788 shares in the last quarter. Avidity Partners Management LP raised its position in Sarepta Therapeutics by 51.3% during the third quarter. Avidity Partners Management LP now owns 450,000 shares of the biotechnology company’s stock valued at $54,549,000 after purchasing an additional 152,500 shares in the last quarter. Finally, Canada Pension Plan Investment Board increased its holdings in shares of Sarepta Therapeutics by 614.3% in the third quarter. Canada Pension Plan Investment Board now owns 145,724 shares of the biotechnology company’s stock worth $17,665,000 after buying an additional 125,324 shares during the period. 86.68% of the stock is owned by institutional investors.

Sarepta Therapeutics Trading Up 2.5 %

Shares of Sarepta Therapeutics stock opened at $127.39 on Friday. The company has a fifty day moving average of $126.22 and a 200 day moving average of $110.43. Sarepta Therapeutics, Inc. has a fifty-two week low of $55.25 and a fifty-two week high of $159.89. The company has a market capitalization of $11.96 billion, a P/E ratio of -20.82 and a beta of 0.94. The company has a debt-to-equity ratio of 1.32, a quick ratio of 3.45 and a current ratio of 3.95.

Sarepta Therapeutics (NASDAQ:SRPT) last released its quarterly earnings data on Wednesday, February 28th. The biotechnology company reported $0.47 EPS for the quarter, beating the consensus estimate of ($0.03) by $0.50. Sarepta Therapeutics had a negative net margin of 43.11% and a negative return on equity of 18.97%. The business had revenue of $396.80 million during the quarter, compared to the consensus estimate of $387.18 million. During the same quarter in the prior year, the firm earned ($1.24) EPS. The business’s revenue was up 53.6% on a year-over-year basis. On average, sell-side analysts anticipate that Sarepta Therapeutics, Inc. will post 2.13 earnings per share for the current fiscal year.

Wall Street Analysts Forecast Growth

Several research firms recently issued reports on SRPT. BMO Capital Markets initiated coverage on Sarepta Therapeutics in a research note on Wednesday, January 31st. They issued an “outperform” rating and a $170.00 target price on the stock. UBS Group boosted their price objective on shares of Sarepta Therapeutics from $164.00 to $167.00 and gave the stock a “buy” rating in a report on Friday, March 1st. Barclays boosted their target price on shares of Sarepta Therapeutics from $141.00 to $185.00 and gave the company an “overweight” rating in a research note on Thursday, February 29th. Mizuho boosted their price objective on shares of Sarepta Therapeutics from $130.00 to $145.00 and gave the company a “buy” rating in a research report on Wednesday, February 14th. Finally, Evercore ISI boosted their price objective on shares of Sarepta Therapeutics from $108.00 to $138.00 and gave the company an “in-line” rating in a research report on Tuesday, February 20th. Four research analysts have rated the stock with a hold rating and twelve have issued a buy rating to the stock. According to MarketBeat.com, Sarepta Therapeutics has a consensus rating of “Moderate Buy” and an average target price of $158.38.

Insider Buying and Selling at Sarepta Therapeutics

In other Sarepta Therapeutics news, insider Bilal Arif sold 2,000 shares of the stock in a transaction dated Friday, March 1st. The shares were sold at an average price of $128.84, for a total transaction of $257,680.00. Following the completion of the transaction, the insider now owns 26,836 shares of the company’s stock, valued at approximately $3,457,550.24. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which can be accessed through the SEC website. In other Sarepta Therapeutics news, insider Bilal Arif sold 2,000 shares of the stock in a transaction dated Friday, March 1st. The shares were sold at an average price of $128.84, for a total transaction of $257,680.00. Following the completion of the transaction, the insider now owns 26,836 shares of the company’s stock, valued at approximately $3,457,550.24. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which can be accessed through the SEC website. Also, CFO Ian Michael Estepan sold 1,200 shares of the company’s stock in a transaction dated Friday, March 1st. The shares were sold at an average price of $128.30, for a total transaction of $153,960.00. Following the sale, the chief financial officer now owns 39,114 shares in the company, valued at $5,018,326.20. The disclosure for this sale can be found here. Insiders sold 22,096 shares of company stock valued at $2,739,419 in the last 90 days. Insiders own 7.40% of the company’s stock.

Sarepta Therapeutics Company Profile

Sarepta Therapeutics, Inc, a commercial-stage biopharmaceutical company, focuses on the discovery and development of RNA-targeted therapeutics, gene therapies, and other genetic therapeutic modalities for the treatment of rare diseases. It offers EXONDYS 51 injection to treat duchenne muscular dystrophy (duchenne) in patients with confirmed mutation of the dystrophin gene that is amenable to exon 51 skipping; VYONDYS 53 for the treatment of duchenne in patients with confirmed mutation of the dystrophin gene that is amenable to exon 53 skipping; AMONDYS 45 for the treatment of duchenne in patients with confirmed mutation of the dystrophin gene; and ELEVIDYS, an adeno-associated virus based gene therapy for the treatment of ambulatory pediatric patients aged 4 through 5 years with duchenne with a confirmed mutation in the duchenne gene.